Jim Simons
NMRA icon

Jim Simons’s Neumora Therapeutics NMRA Stock Holding History

Jim Simons’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.15M Sell
1,262,304
-126,694
-9% -$241K ﹤0.01% 1917
2026
Q1 		$2.71M Sell
1,388,998
-56,904
-4% -$147K ﹤0.01% 1711
2025
Q4 		$2.59M Buy
1,445,902
+281,926
+24% +$617K ﹤0.01% 1704
2025
Q3 		$2.12M Sell
1,163,976
-270,551
-19% -$437K ﹤0.01% 2035
2025
Q2 		$1.05M Buy
1,434,527
+174,997
+14% +$133K ﹤0.01% 2492
2025
Q1 		$1.26M Buy
+1,259,530
New +$2.16M ﹤0.01% 2262
2024
Q2 		– Sell
-138,900
Closed -$1.91M – 3814
2024
Q1 		$1.91M Buy
138,900
+125,300
+921% +$2.03M ﹤0.01% 2060
2023
Q4 		$232K Buy
+13,600
New +$167K ﹤0.01% 3082

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jim Simons's NMRA Position: Q2 2026 in Review

Jim Simons reduced its Neumora Therapeutics (NMRA) stake by 9.1% in Q2 2026, selling an estimated $241K and leaving 1,262,304 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Jim Simons first reported a position in NMRA in Q4 2023 and has held it in 8 quarters since. The position peaked at $2.71M in Q1 2026. 68 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Jim Simons held 1,262,304 shares of Neumora Therapeutics worth $2.15M as of Q2 2026.
  • Jim Simons sold 126,694 Neumora Therapeutics shares in Q2 2026, an estimated $241K.
  • Neumora Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #1917 holding.
  • Jim Simons first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • Jim Simons's Neumora Therapeutics position peaked at $2.71M in Q1 2026.
  • 68 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.